全文获取类型
收费全文 | 4092篇 |
免费 | 258篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 126篇 |
妇产科学 | 94篇 |
基础医学 | 767篇 |
口腔科学 | 135篇 |
临床医学 | 338篇 |
内科学 | 724篇 |
皮肤病学 | 138篇 |
神经病学 | 606篇 |
特种医学 | 140篇 |
外科学 | 412篇 |
综合类 | 23篇 |
一般理论 | 2篇 |
预防医学 | 223篇 |
眼科学 | 67篇 |
药学 | 293篇 |
中国医学 | 2篇 |
肿瘤学 | 256篇 |
出版年
2024年 | 2篇 |
2023年 | 38篇 |
2022年 | 52篇 |
2021年 | 97篇 |
2020年 | 82篇 |
2019年 | 113篇 |
2018年 | 98篇 |
2017年 | 74篇 |
2016年 | 111篇 |
2015年 | 128篇 |
2014年 | 166篇 |
2013年 | 168篇 |
2012年 | 308篇 |
2011年 | 335篇 |
2010年 | 191篇 |
2009年 | 192篇 |
2008年 | 317篇 |
2007年 | 296篇 |
2006年 | 284篇 |
2005年 | 246篇 |
2004年 | 281篇 |
2003年 | 241篇 |
2002年 | 212篇 |
2001年 | 23篇 |
2000年 | 25篇 |
1999年 | 39篇 |
1998年 | 40篇 |
1997年 | 34篇 |
1996年 | 26篇 |
1995年 | 23篇 |
1994年 | 28篇 |
1993年 | 20篇 |
1992年 | 14篇 |
1991年 | 14篇 |
1990年 | 4篇 |
1989年 | 3篇 |
1986年 | 10篇 |
1985年 | 3篇 |
1984年 | 4篇 |
1982年 | 2篇 |
1980年 | 2篇 |
1976年 | 5篇 |
1975年 | 2篇 |
1971年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1960年 | 1篇 |
1947年 | 1篇 |
1946年 | 1篇 |
1940年 | 1篇 |
排序方式: 共有4367条查询结果,搜索用时 15 毫秒
81.
82.
83.
Ohne Zusammenfassung 相似文献
84.
85.
86.
Jasmin Hasmik Shahinian Eva A. Rog-Zielinska Manuel Schlimpert Bettina Mayer Stefan Tholen Bernd Kammerer Martin L. Biniossek Friedhelm Beyersdorf Oliver Schilling Matthias Siepe 《Artificial organs》2020,44(3):257-267
The changes in the myocardial proteome and metabolome associated with left ventricular assist device (LVAD) therapy in patients with ischemic cardiomyopathy (ICM) are poorly characterized. We investigated the impact of mechanical unloading following LVAD therapy on the myocardial proteome and metabolome. Matched samples of 5 patients’ myocardial tissue, harvested at the time of LVAD implant (“pre-LVAD”) or heart transplant (“post-LVAD”), were studied by quantitative proteomics and metabolomics as well as being probed for T-tubule structure and connexin-43 distribution. Moreover, pre-LVAD proteome profiles of ICM context were bioinformatically compared to pre-LVAD proteome profiles of dilated cardiac myopathy (DCM). More than 2120 proteins were reliably identified and quantified in paired patient samples. LVAD therapy led to proteomic remodeling, including reduced levels of α-1-antichymotrypsin together with an overall decrease of immune response proteins and an increase of proteins involved in membrane biology. Metabolomics highlighted increased glucose and glucose-6-phosphate levels in the left ventricle upon LVAD therapy. Wheat germ agglutinin staining demonstrated improved T-tubule structure. Connexin-43 displayed a trend for more pronounced intercalated disc localization. In comparing pre-LVAD proteome profiles of ICM context with pre-LVAD proteome profiles of dilated cardiac myopathy (DCM), we noticed an overrepresentation in ICM of proteins associated with humoral immune response. Our findings underline an impact of LVAD therapy on left ventricular biology in ICM. The proteomic, metabolomic, and structural alterations described here are typically associated with cardiac recovery. On the molecular level, our findings indicate the possibility of cardiac remodeling under LVAD therapy in ICM. 相似文献
87.
Bettina Kniesel Lukas Konstantinidis Anja Hirschmüller Norbert Südkamp Peter Helwig 《International orthopaedics》2014,38(4):733-739
Purpose
The aim of this study was to determine how well pre-operative size selection for total knee and hip arthroplasties based on the digital imaging with and without additional referencing correlated with the size actually implanted.Methods
Size selection planning of total knee arthroplasty by digital templating was documented in 46 cases with reference ball (group A) and in 48 cases without ball (group B). In addition, prospective analysis of pre-operative planning was conducted for 52 acetabular components with reference ball (group C) and 69 without ball (group D) as well as stem planning in 38 cases with ball (group E) and 54 cases without ball (group F). The data were analysed and compared with the size of the final component selected during surgery.Results
The correlation between planned and implanted size for total knee arthroplasty in group A resulted in femoral anteroposterior (AP) r = 0.8622 and lateral r = 0.8333 and in group B AP r = 0.4552 and lateral r = 0.6950. Tibial in group A was AP r = 0.9030 and lateral r = 0.9074 and in group B AP r = 0.7000 and lateral r = 0.6376. For the acetabular components, the results in group C were r = 0.5998 and group D r = 0.6923. For stems, group E was r = 0.5306 and group F r = 0.5786. No correlation between BMI and the difference between planned and implanted size was found in any of the groups.Conclusion
In the case of total hip arthroplasty there was a relatively low correlation between planned and implanted sizes with or without reference ball. For total knee arthroplasties the already high precision of size planning was further improved by the additional referencing with a reference ball. 相似文献88.
Bettina M. Rau 《World journal of surgery》2014,38(2):456-462
Background
Despite significant improvements in perioperative mortality as well as response rates to multimodality treatment, results after surgical resection of pancreatic adenocarcinoma with respect to long-term outcomes remain disappointing. Patient recruitment for prospective international trials on adjuvant and neoadjuvant regimens is challenging for various reasons. We set out to assess the preconditions and potential to perform perioperative trials for pancreatic cancer within a well-established Austrian nationwide network of surgical and medical oncologists (Austrian Breast & Colorectal Cancer Study Group).Methods
From 2005 to 2010 five high-volume centers and one medium-volume center completed standardized data entry forms with 33 parameters (history and patient related data, preoperative clinical staging and work-up, surgical details and intraoperative findings, postoperative complications, reinterventions, reoperations, 30-day mortality, histology, and timing of multimodality treatment). Outside of the study group, in Austria pancreatic resections are performed in three “high-volume” centers (>10 pancreatic resections per year), three “medium-volume” centers (5–10 pancreatic resections per year), and the rest in various low-volume centers (<5 pancreatic resections per year) in Austria. Nationwide data for prevalence of and surgical resections for pancreatic adenocarcinoma were contributed by the National Cancer Registry of Statistics of Austria and the Austrian Health Institute.Results
In total, 492 consecutive patients underwent pancreatic resection for ductal adenocarcinoma. All postoperative complications leading to hospital readmission were treated at the primary surgical department and documented in the database. Overall morbidity and pancreatic fistula rate were 45.5 % and 10.1 %, respectively. Within the entire cohort there were 9.8 % radiological reinterventions and 10.4 % reoperations. Length of stay was 16 days in median (0–209); 12 of 492 patients died within 30 days after operation, resulting in a 30-day mortality rate of 2.4 %. Seven of the total 19 deaths (36.8 %) occurred after 30 days, during hospitalization at the surgical department, resulting in a hospital mortality rate of 3.9 % (19/492). With a standardized histopathological protocol, there were 70 % (21/30) R0 resections, 30 % (9/30) R1 resections, and no R2 resections in Vienna and 62.7 % (32/51) R0 resections, 35.3 % (18/51) R1 resections, and 2 % (1/51) R2 resections in Salzburg. Resection margin status with nonstandardized protocols was classified as R0 in 82 % (339/411), R1 in 16 % (16/411), and R2 in 1.2 % (5/411). Perioperative chemotherapy was administered in 81.1 % of patients (8.3 % neoadjuvant; 68.5 % adjuvant; 4.3 % palliative); chemoradiotherapy (1.6 % neoadjuvant; 3 % adjuvant; 0.2 % palliative), in 4.9 % of patients. The six centers that contributed to this registry initiative provided surgical treatment to 40 % of all Austrian patients, resulting in a median annual recruitment of 85 (51–104) patients for the entire ABCSG-group and a median of 11.8 (0–38) surgeries for each individual department.Conclusions
Surgical quality data of the ABCSG core pancreatic group are in line with international standards. With continuing centralization the essential potential to perform prospective clinical trials for pancreatic adenocarcinoma is given in Austria. Several protocol proposals aiming at surgical and multimodality research questions are currently being discussed. 相似文献89.
90.